Edgewise's Leerink Test: Can It Hold $28.88 or Break Below?

The stock is at a crossroads. After a 4.1% drop over the last five days, it now trades at $28.88. That pullback comes just days before a major event: Edgewise leadership is scheduled to present at the Leerink Global Healthcare Conference on March 11, 2026, at 1:40 p.m. ET. This is a high-visibility catalyst, a direct line to institutional investors and analysts who will scrutinize the company's progress.

The setup is classic event-driven tension. The stock has already run 96.9% over the last 120 days, a massive surge that leaves it vulnerable to any sign of weakness. The recent decline suggests some profit-taking or skepticism is already in play. The Leerink presentation is the next test. A strong update on its late-stage programs could halt the slide and retest the 52-week high of $31.82. Conversely, if the news is merely incremental or fails to address underlying concerns, the momentum could reverse, driving the stock lower from these elevated levels. For now, the market is waiting to see which story the catalyst confirms.

The Data on the Table: MDA Results and the Functional Divergence

The Leerink presentation will be judged against a recent, high-stakes benchmark: the data Edgewise just shared at the Muscular Dystrophy Association conference earlier this month. That event provided the first public look at its late-stage sevasemten program for Becker muscular dystrophy, setting a clear standard for what a positive update would look like.

Bullish data points are compelling. The company highlighted a 23-point mean increase on a cardiomyopathy questionnaire at the 100 mg dose after four weeks, a result that surpasses previous trials. More broadly, sevasemten showed over a 30% improvement in average daily activity. These are strong signals of patient benefit and functional impact, which are critical for regulatory and commercial success.

Yet the bear case is anchored in a stark divergence. The new data includes results from the MESA open-label extension, which revealed a notable divergence in functional decline measures from expected patterns in Becker studies. Specifically, the control group showed a 28% average decrease in NSAA scores over months six through twelve. This is a major red flag. In a disease where progression is typically slow, a 28% functional decline in a control arm over a year suggests the natural history data may be more aggressive than previously modeled. It raises the bar for the drug to show a clear, statistically significant benefit over placebo in a pivotal trial.

The bottom line is that the Leerink presentation must directly address this tension. A positive update would need to not only reiterate the strong questionnaire and activity gains but also provide a clear explanation for the control group's rapid decline and demonstrate how sevasemten's effect size overcomes this steeper baseline. If the company fails to resolve this divergence, the stock's recent momentum faces a serious test.

The Risk/Reward: From Current Price to Analyst Targets

The immediate setup is clear. The stock is trading at $28.88, down from a 52-week high of $31.82. Its valuation reflects its clinical-stage status, with a forward P/E of -20.1. This negative multiple is a direct result of the company's lack of near-term profits; investors are paying for future potential, not current earnings.

Against this, the analyst consensus paints a bullish picture. The Street has a Buy rating with a $37.30 price target. That implies roughly 29% upside from current levels, a significant premium that underscores the high expectations priced in. The target is not a guarantee, but it sets a clear benchmark for a positive catalyst to clear.

So, what would constitute that catalyst? It needs to be clear and compelling data that reassures investors about the drug's efficacy and path to approval. The Leerink presentation is the stage for this. The company must not only reiterate the strong questionnaire and activity gains but also directly address the concerning control group data from the MESA extension. A positive update would need to demonstrate that sevasemten's benefit size is robust enough to overcome the steeper baseline decline observed in the placebo arm. If it does, the stock could retest the 52-week high and potentially move toward the analyst target. If the news is merely incremental or fails to resolve the divergence, the recent momentum faces a serious test, and the stock could break below current levels. The risk/reward is defined by that single event.

What to Watch: The 1:40 PM ET Signal

The stock's immediate direction hinges on a single, time-bound event. The presentation begins at 1:40 p.m. ET on March 11. The first test will be the live price reaction around that start time, a direct signal of how the market digests the opening remarks.

Bulls will be looking for specific, forward-looking signals. Management must provide clarity on the pivotal Becker trial timeline, including any updates on enrollment, planned endpoints, or regulatory strategy. A confident tone on overcoming the disease's natural history, backed by a clear plan, would be the bullish catalyst. The company's pipeline page confirms sevasemten is in the Pivotal / Phase 3 stage for Becker, making this timeline critical.

The key risk is failure to address the functional decline divergence. The bear case centers on the 28% average decrease in NSAA scores in the control group over months six through twelve. If the presentation merely reiterates the positive questionnaire gains without directly explaining or contextualizing this steep decline, it validates the most concerning data point. That would likely trigger a negative price reaction, as it suggests the drug's benefit may be harder to demonstrate than hoped.

The bottom line is that the 1:40 PM ET signal is binary. A clear, reassuring update on the pivotal path could halt the recent slide and retest higher levels. But if the company sidesteps the control group data or offers no new insight, the stock faces a high probability of breaking below its current price, confirming the bearish setup. The market will be watching for the first concrete answer to the question that has been driving the volatility.